Marshall Wace
ADAP

Marshall Wace’s Adaptimmune Therapeutics ADAP Stock Holding History

Marshall Wace’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-529,123
Closed -$286K – 2585
2024
Q4 		$286K Buy
529,123
+6,515
+1% +$4.75K ﹤0.01% 2247
2024
Q3 		$496K Buy
522,608
+377,728
+261% +$429K ﹤0.01% 1919
2024
Q2 		$141K Sell
144,880
-109,133
-43% -$120K ﹤0.01% 2361
2024
Q1 		$401K Buy
+254,013
New +$307K ﹤0.01% 2015
2023
Q3 		– Sell
-272,681
Closed -$254K – 2136
2023
Q2 		$254K Buy
+272,681
New +$325K ﹤0.01% 2182
2023
Q1 		– Sell
-89,171
Closed -$130K – 2594
2022
Q4 		$130K Buy
+89,171
New +$144K ﹤0.01% 2763
2022
Q1 		– Sell
-567,796
Closed -$2.13M – 3275
2021
Q4 		$2.13M Sell
567,796
-986,004
-63% -$4.49M ﹤0.01% 2000
2021
Q3 		$8.03M Buy
+1,553,800
New +$6.97M 0.03% 684
2020
Q3 		– Sell
-376,340
Closed -$3.77M – 1535
2020
Q2 		$3.77M Buy
+376,340
New +$2.36M 0.03% 567
2020
Q1 		– Sell
-29,102
Closed -$35K – 1590
2019
Q4 		$35K Sell
29,102
-50,146
-63% -$53.5K ﹤0.01% 1571
2019
Q3 		$120K Buy
+79,248
New +$185K ﹤0.01% 1371
2019
Q1 		– Sell
-130,050
Closed -$748K – 1679
2018
Q4 		$748K Buy
+130,050
New +$960K 0.01% 991
2016
Q1 		– Sell
-140,983
Closed -$1.7M – 1009
2015
Q4 		$1.7M Buy
+140,983
New +$1.38M 0.02% 596

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's ADAP Position: Q1 2025 in Review

Marshall Wace sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 529,123 shares — an estimated $286K sold.

Marshall Wace first reported a position in ADAP in Q4 2015 and held it in 13 quarters. The position peaked at $8.03M in Q3 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Marshall Wace reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Marshall Wace sold 529,123 Adaptimmune Therapeutics shares in Q1 2025, an estimated $286K.
  • Marshall Wace first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 13 quarters.
  • Marshall Wace's Adaptimmune Therapeutics position peaked at $8.03M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.